Caraco Pharmaceutical Laboratories Ltd

Caraco Pharmaceutical Laboratories — Investor Presentation (October 2008)

23 slides from Caraco Pharmaceutical Laboratories's investor presentation, Oct 30, 2008

  1. Slide 1: Driving Value

    Driving Value Providing value with quality generics Investor Presentation

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause

  3. Slide 3: Steady Growth

    Steady Growth *Change in Fiscal year. Covers transition period from 1/1/2005 to 3/31/2005 (25) F2005* F2006 F2007 F2008 Net Sales - F2005* F2006 F2007 F2008 Gross Profit

  4. Slide 4: Annual Results

    Annual Results *Change in Fiscal year. Covers transition period from 1/1/2005 to 3/31/2005 (0) -4 -10 (25) F2005* F2006 F2007 F2008 Net Sales Gross Profit Net Income Cash Flow from operations

  5. Slide 5: Second Quarter Fiscal Results

    Second Quarter Fiscal 09 Results (27) Q4-F2007 Q1-F2008 Q2-F2008 Q3-F2008 Q4-F2008 Q1-F2009 Q2-F2009 Net Sales Gross Profit Net Income Cash Flow From Operations

  6. Slide 6: Gross Profit Mix

    Gross Profit Mix Consistent base from Manufactured Products Distributed Product Margin provides growth and funding for new business opportunities $0 $5,000,000 $10,000,000 $15,000,000 $20,000,000 $25,000,000 $30,000,000 $35,000,000 Manufactured Gross Profit Distributed Product Gross Profit Six Month

  7. Slide 7: Peer Group Analysis

    Peer Group Analysis P/E Ratios (10/28/08/TTM) 8.4 18.6 14.8 9.7 25.4 N/A 0x 5x 10x 15x 20x 25x 30x Caraco Pharmaceuticals Laboratories Mylan Perrigo Co. Teva Pharmaceutical Industries Ltd. Watson Pharmaceuticals Inc. KV Pharmaceutical Co. Dr Reddy’s Laboratories Ltd

  8. Slide 8: Peer Group Analysis

    Peer Group Analysis Price/Sales Ratios (10/28/08/TTM) 0.6 0.5 1.5 3.2 1.3 1.3 0x 1x 1x 2x 2x 3x 3x 4x Caraco Pharmaceuticals Laboratories Mylan Perrigo Co. Teva Pharmaceutical Industries Ltd. Watson Pharmaceuticals Inc. KV Pharmaceutical Co. Dr Reddy’s Laboratories Ltd

  9. Slide 9: Peer Group Analysis

    Peer Group Analysis Price/Cash Flow Ratios (10/28/08/TTM) 6.9 13.3 14.2 6.4 6.2 15.8 N/A 0x 2x 4x 6x 8x 10x 12x 14x 16x 18x Caraco Pharmaceuticals Laboratories Mylan Perrigo Co. Teva Pharmaceutical Industries Ltd. Watson Pharmaceuticals Inc. KV Pharmaceutical Co. Dr Reddy’s Laboratories Ltd

  10. Slide 10: Generic Pharmaceutical Industry Overview

    Generic Pharmaceutical Industry Overview The Generic Pharmaceutical Industry primarily consists of generic versions of brand pharmaceuticals that have lost their patent exclusivity or are products that do not infringe the innovator’s patent U.S. brand pharmaceutical sales for 2007 were $228 billion.

  11. Slide 11: Caraco Overview

    Caraco Overview Established in 1984, based in Detroit, MI Caraco develops, manufactures, markets and distributes generic and private-label pharmaceuticals In 1997, Sun Pharmaceutical Industries, Ltd. invested $7.5 million in Caraco through a stock purchase agreement In 2002, Caraco signed an agreeme

  12. Slide 12: Caraco Overview

    Caraco Overview Received the Following Recognition: Business Week Magazine’s Hot Growth 50: Top Ten Best Small Companies 2008 Listed within Deloitte’s Technology Fast 500 List 2007 Named as One of the “Fastest Growing Companies by Percentage of Change in Revenue” in Metro Detroit by Crain’s Business

  13. Slide 13: Sun Pharmaceutical Industries, Ltd.

    Sun Pharmaceutical Industries, Ltd. Established in 1983, Sun is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. I

  14. Slide 14: Sun Involvement in Caraco

    Sun Involvement in Caraco In 1997, Sun invested $7.5 million in Caraco through a stock purchase agreement Caraco recently completed the Technology Transfer Agreement signed in 2002 with Sun for 25 products At the beginning of calendar 2007, Caraco entered into a definitive agreement to market Sun AN

  15. Slide 15: Caraco's Drivers Fiscal 2009

    Caraco’s Drivers Fiscal 2009 FDA product approvals Maximize market share on current portfolio Improve operational execution Streamline processes and reduce operational costs

  16. Slide 16: Strong Pipeline

    Strong Pipeline Caraco Pipeline Sun Advantage Definitive agreements to market Sun ANDAs Internal Development Focused on generic opportunities that add to manufactured product basket Outsourced Development Four products being developed by third party developers Additional products under review Togeth

  17. Slide 17: Caraco Development Pipeline

    Caraco Development Pipeline Fiscal 2007 Fiscal 2008 Fiscal 2009 Number of ANDA Filings Products Filed ANDAs Awaiting Approval Products Awaiting Approval

  18. Slide 18: Product Litigation

    Product Litigation Lexapro - Forest has two U.S. patents listed with the FDA that they claim cover Lexapro, the ’712 patent and the ’941 patent. We filed an ANDA in which we certified to the noninfringement and/or invalidity of both patents. On July 10, 2006, Forest sued us on the ’712 patent in fed

  19. Slide 19: Current Portfolio

    Current Portfolio Caraco’s current product portfolio consists of 53 products in 115 strengths 27 of our products are in the top three of generic market share Vertical integration with Sun allows us to enjoy longer lifecycles and value on products that we market

  20. Slide 20: Caraco Capacity

    Caraco Capacity At the start of 2007, facilities included 114,000 sq ft owned and 67,000 sq ft leased for total footprint of approximately 180,000 sq ft 2008 Additions Acquired and opened 135,000 sq ft distribution warehouse, Building expansion underway on a 140,000 square foot state-of-the-art phar

  21. Slide 21: Why Caraco?

    Why Caraco? Management Experienced in the industry Disciplined Focused on cost containment Proven ability to execute Sun Relationship Strong R&D capability Vertical integration via API’s Ability to offshore product manufacturing Balanced approach of Para IVs, blockbuster and niche products Product P

  22. Slide 22: Why Caraco?

    Why Caraco? Strong Customer Relationships Management of trade class mix offers a sense of predictability Strong Fundamental Financial Position Positive Cash Position No Debt Positioned for strategic acquisitions Value Compared to Peer Group Guidance At least 10 products to be filed in Fiscal 2009 25

  23. Slide 23: Thank You

    Thank You For updates and specific queries, please visit www.caraco.com or feel free to contact Tom Versosky Tel : (313) 556-4150 [email protected] Daniel Movens Tel : (313) 871-8400 [email protected]

Caraco Pharmaceutical Laboratories — Investor Presentation (October 2008) on 6ix